
|Articles|January 27, 2021
Supplements and Featured Publications
- The Role of Lipoprotein(a) As a Biomarker to Assess Cardiovascular Risk
The Role of Lipoprotein(a) As a Biomarker to Assess Cardiovascular Risk
Advertisement
This publication is sponsored by Novartis AG.
This Clinical Practice Brief provides an overview of the genetic cardiovascular risk biomarker lipoprotein a (Lp[a]), as well as its importance as an independent risk factor for cardiovascular disease, the prevalence of elevated Lp(a) levels among the global population, and recommendations for lipid management.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
NYC Nurses Strike Enters Day 5 Amid Staffing, Safety, and Benefit Disputes
2
Respiratory Vaccination by the Numbers: COVID-19, Flu, and RSV
3
Anti-Inflammatory, Antioxidant-Rich Diets May Lower Skin Cancer Risk, Slow Biological Aging
4
Lipid Management Remains Central to Cardiovascular Risk Reduction in CKD
5




























































